CA1249194A - Arrangement for applying a tissue adhesive - Google Patents
Arrangement for applying a tissue adhesiveInfo
- Publication number
- CA1249194A CA1249194A CA000511285A CA511285A CA1249194A CA 1249194 A CA1249194 A CA 1249194A CA 000511285 A CA000511285 A CA 000511285A CA 511285 A CA511285 A CA 511285A CA 1249194 A CA1249194 A CA 1249194A
- Authority
- CA
- Canada
- Prior art keywords
- chamber
- syringe
- syringe bodies
- bodies
- syringe body
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 239000003106 tissue adhesive Substances 0.000 title claims abstract description 12
- 239000012460 protein solution Substances 0.000 claims abstract description 15
- 229960004072 thrombin Drugs 0.000 claims abstract description 15
- 108090000190 Thrombin Proteins 0.000 claims abstract description 14
- 108010049003 Fibrinogen Proteins 0.000 claims abstract description 11
- 102000008946 Fibrinogen Human genes 0.000 claims abstract description 11
- 229940012952 fibrinogen Drugs 0.000 claims abstract description 11
- 108010039209 Blood Coagulation Factors Proteins 0.000 claims abstract description 4
- 102000015081 Blood Coagulation Factors Human genes 0.000 claims abstract description 4
- 208000007536 Thrombosis Diseases 0.000 claims abstract description 4
- 239000003114 blood coagulation factor Substances 0.000 claims abstract description 4
- 239000000243 solution Substances 0.000 claims description 17
- 239000012530 fluid Substances 0.000 claims description 15
- 239000000853 adhesive Substances 0.000 claims description 10
- 230000001070 adhesive effect Effects 0.000 claims description 10
- 238000005304 joining Methods 0.000 claims description 6
- 239000002904 solvent Substances 0.000 claims description 6
- 108010039627 Aprotinin Proteins 0.000 claims description 4
- 229960004405 aprotinin Drugs 0.000 claims description 4
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 claims description 4
- 238000011065 in-situ storage Methods 0.000 claims description 3
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims description 2
- 229910001628 calcium chloride Inorganic materials 0.000 claims description 2
- 239000001110 calcium chloride Substances 0.000 claims description 2
- 241001465754 Metazoa Species 0.000 abstract description 2
- 235000021120 animal protein Nutrition 0.000 abstract description 2
- 210000000056 organ Anatomy 0.000 abstract description 2
- 229940075469 tissue adhesives Drugs 0.000 abstract 1
- 238000004090 dissolution Methods 0.000 description 9
- 235000018102 proteins Nutrition 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 238000005266 casting Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 208000032843 Hemorrhage Diseases 0.000 description 2
- 208000031737 Tissue Adhesions Diseases 0.000 description 2
- 206010052428 Wound Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 208000034158 bleeding Diseases 0.000 description 2
- 231100000319 bleeding Toxicity 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 235000004252 protein component Nutrition 0.000 description 2
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 108010071289 Factor XIII Proteins 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000002542 deteriorative effect Effects 0.000 description 1
- MCWXGJITAZMZEV-UHFFFAOYSA-N dimethoate Chemical compound CNC(=O)CSP(=S)(OC)OC MCWXGJITAZMZEV-UHFFFAOYSA-N 0.000 description 1
- 229940012444 factor xiii Drugs 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- JCYWCSGERIELPG-UHFFFAOYSA-N imes Chemical class CC1=CC(C)=CC(C)=C1N1C=CN(C=2C(=CC(C)=CC=2C)C)[C]1 JCYWCSGERIELPG-UHFFFAOYSA-N 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 238000007711 solidification Methods 0.000 description 1
- 230000008023 solidification Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/00491—Surgical glue applicators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/19—Syringes having more than one chamber, e.g. including a manifold coupling two parallelly aligned syringes through separate channels to a common discharge assembly
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/00491—Surgical glue applicators
- A61B2017/00495—Surgical glue applicators for two-component glue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/28—Syringe ampoules or carpules, i.e. ampoules or carpules provided with a needle
- A61M5/284—Syringe ampoules or carpules, i.e. ampoules or carpules provided with a needle comprising means for injection of two or more media, e.g. by mixing
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Surgery (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Vascular Medicine (AREA)
- Anesthesiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Medical Informatics (AREA)
- Molecular Biology (AREA)
- Materials For Medical Uses (AREA)
- Surgical Instruments (AREA)
- Treatments For Attaching Organic Compounds To Fibrous Goods (AREA)
Abstract
ABSTRACT OF THE DISCLOSURE:
An arrangement for applying a tissue adhesive based on human or animal proteins, to seamlessly or seam-supportingly connect human or animal tissue or organ parts by uniting with blood-clot-promoting coagulation factors (thrombin). The arrangement includes a plurality of syringe bodies commonly actuatable by pistons and to which a connecting head is attachable. The syringe bodies have equal effective strokes, yet one of them, i.e., that destined to contain the protein solution, has a cross sectional area that is two to nine times larger than the other one(s). There may be applied tissue adhesives having a fibrinogen content of from 2 to 12 %.
An arrangement for applying a tissue adhesive based on human or animal proteins, to seamlessly or seam-supportingly connect human or animal tissue or organ parts by uniting with blood-clot-promoting coagulation factors (thrombin). The arrangement includes a plurality of syringe bodies commonly actuatable by pistons and to which a connecting head is attachable. The syringe bodies have equal effective strokes, yet one of them, i.e., that destined to contain the protein solution, has a cross sectional area that is two to nine times larger than the other one(s). There may be applied tissue adhesives having a fibrinogen content of from 2 to 12 %.
Description
~Z~94 The invention relates to an arrangement for applying a tlssue adhesive based on human or animal proteins, to seamlessly or seam-supportingly connect human or animal tissue or organ parts, seal wounds, stop bleedings and the like, which tissue adhesive solidifies in situ by uniting with blood-clot-promoting coagulation factors, which arrangement comprises a plurality of syringe bodies ending in joining pieces and commonly actuatable by pistons to contain the components to be applied, wherein a connecting head is attachable to the joining pieces of the syringe bodies, w~ich includes a separate conveying channel for each of the components to be applied and optionally for a medical propellant.
An arrangement of this type is described in U.S.
patent No. 4,359,049. As components, a protein solution ~; containing factor XIII and fibrinogen (tissue adhesive), ~`
on the one hand, and a solution containing thrombin, on the other hand, may be used. The components are mixed in a mixing needle attached to the connecting head and are
An arrangement of this type is described in U.S.
patent No. 4,359,049. As components, a protein solution ~; containing factor XIII and fibrinogen (tissue adhesive), ~`
on the one hand, and a solution containing thrombin, on the other hand, may be used. The components are mixed in a mixing needle attached to the connecting head and are
2~ applied onto the wound area to be treated or protected.
~ When realizing tissue adhesions or treatments, the ;~; protein solution and the thxombin solution usually are ~ obtained by dissolving lyophilisates. In doing so, one may ;~ ~
be faced with the problem, in particular in a surgical emergency situation, that the preparation of the protein solution takes an undesirably long time because of the poor solubility of these components. It is, of course, possible to shorten the dissolution time o~ the protein :~P
~12~
2424~-418 component hy usin~ a larcJer amount of solvent, yet, when mixing the protein solution with the -thrombin solution at a volume ratio of 1 : 1, as has been common practice so far, even the clotting mlxture is diluted to such an extent that a significant reduction in the ultimate tensile strength of the adhesion consequently will occur.
The invention aims at avolding this difficulty and has as its object to desi~n the known arrangement with a view to shortening the dissolution time when preparing a protein solution from ~ lyophilisate, without reducing the ultimate ténsile strength of the adhesion.
According to one broad aspect of the invention there is provided an arrangement for applying a tissue adhesive that - solidifies in situ by uniting with blood-clot-promoting coagulation factors, comprising:
a plurality of syringe bodies ending in joining pieces;
a piston in each of said plurality of syringe bodies for commonly actuating said syringe bodies;
a connecting head attached to said joining pieces of said syringe bodies and provided with a separate conveying channel for each of the componenks to he applied;
each of said syringe bodies having equally effective ,~
`~ strokes; and one of said syringe bodies having a cross-sectional area that is two to nine times laryer than the cross-sectional area of the remaining syringe bodies, said one syrlnge body containing an adhesive proteln solution having a fibrinogen content of from 3 to 12%.
'~
2~
24242-4~8 According to another broad aspecl of ~he invention there is provided a device for dispensing a plurality of interreactable flu,Ld, comprisin~:
a p~urality of syringe bodies a connectiny head intereonnecting the discharge ends of each of ~he syringe bodies;
first piston means in each of said syrinye hodies ~or actuating said syringe bodies;
first floating piston means in one o~ said syringe`bodies for dividiny said one syringe body into a first chamb~r and a second chamber; and first by-pass means in said one syringe body for allowing fluid from said second chamber to mix with fluid in said first by-pass means in said one syrlnge body for allowing fluid from said second chamber to mix with fluid in said first chamber when said first floating piston mean,s is adjacent said first by-pass means;
wherein sald one syringe body has a cross-sectional area that is two to nine ~.imes larger than the cross-secti~nal area ~'- 20 of the remaining syringe bodies.
According to a preferred embodiment, the syringe bodies may be designed as twin-chamber syringe bodies, with the - protein and the thrombin components heing stored in the mouth-side chambers in lyophilized form and the solvent being containecl in the remaining chambers.
~' Whila the protein solutions used for tissue adhesions so far have had fibrinogen contents of about 10% ~100 ~' ; 30
~ When realizing tissue adhesions or treatments, the ;~; protein solution and the thxombin solution usually are ~ obtained by dissolving lyophilisates. In doing so, one may ;~ ~
be faced with the problem, in particular in a surgical emergency situation, that the preparation of the protein solution takes an undesirably long time because of the poor solubility of these components. It is, of course, possible to shorten the dissolution time o~ the protein :~P
~12~
2424~-418 component hy usin~ a larcJer amount of solvent, yet, when mixing the protein solution with the -thrombin solution at a volume ratio of 1 : 1, as has been common practice so far, even the clotting mlxture is diluted to such an extent that a significant reduction in the ultimate tensile strength of the adhesion consequently will occur.
The invention aims at avolding this difficulty and has as its object to desi~n the known arrangement with a view to shortening the dissolution time when preparing a protein solution from ~ lyophilisate, without reducing the ultimate ténsile strength of the adhesion.
According to one broad aspect of the invention there is provided an arrangement for applying a tissue adhesive that - solidifies in situ by uniting with blood-clot-promoting coagulation factors, comprising:
a plurality of syringe bodies ending in joining pieces;
a piston in each of said plurality of syringe bodies for commonly actuating said syringe bodies;
a connecting head attached to said joining pieces of said syringe bodies and provided with a separate conveying channel for each of the componenks to he applied;
each of said syringe bodies having equally effective ,~
`~ strokes; and one of said syringe bodies having a cross-sectional area that is two to nine times laryer than the cross-sectional area of the remaining syringe bodies, said one syrlnge body containing an adhesive proteln solution having a fibrinogen content of from 3 to 12%.
'~
2~
24242-4~8 According to another broad aspecl of ~he invention there is provided a device for dispensing a plurality of interreactable flu,Ld, comprisin~:
a p~urality of syringe bodies a connectiny head intereonnecting the discharge ends of each of ~he syringe bodies;
first piston means in each of said syrinye hodies ~or actuating said syringe bodies;
first floating piston means in one o~ said syringe`bodies for dividiny said one syringe body into a first chamb~r and a second chamber; and first by-pass means in said one syringe body for allowing fluid from said second chamber to mix with fluid in said first by-pass means in said one syrlnge body for allowing fluid from said second chamber to mix with fluid in said first chamber when said first floating piston mean,s is adjacent said first by-pass means;
wherein sald one syringe body has a cross-sectional area that is two to nine ~.imes larger than the cross-secti~nal area ~'- 20 of the remaining syringe bodies.
According to a preferred embodiment, the syringe bodies may be designed as twin-chamber syringe bodies, with the - protein and the thrombin components heing stored in the mouth-side chambers in lyophilized form and the solvent being containecl in the remaining chambers.
~' Whila the protein solutions used for tissue adhesions so far have had fibrinogen contents of about 10% ~100 ~' ; 30
-3~-~9199L
mg/ml) or more, diluted protein solut:ions with fibrinogen cont.ents of from 2 to 7 ~ may be used accordiny to the invention, or there may be achieved adhesions of higher strengths when using protein solutions having fibrinogen contents of up to 12 %.
The invention is based on the principle that a favorable ra~io between the necessary reconstitution time of the protein lyophilisate and the strength of the adhesions will be obtained, if the hitherto usual mixing ratio of the protein solution and the thrombin solution of 1 is altered such that the protein component is dissolved in a relatively larger volume and the thrombin component is dissolved in a relatively smaller volume to compensate for the resulting lower protein concentration ~- of the protein component in the mixture of the two components.
If, however, adhesions of particularly high strengths are sought, an increase in the concentration of the adhesive proteins may be obtained according to the invention after having mixed the two components, without having to put up with~extended reconstitution times.
Mixing the two components in a su~ici~ntly exact ratio that deviates from 1 would be too difficult when using two separate syringes and has become possible only by the double syringe according to the invention.
The arrangement accordlng to the invention will now be explalned in more de-tail by way of two em~odiments and with reference -to the accompanying drawing, w~erein Figs.
1 an-l 2 are each a par~ially sectioned sidt3 vi63w oE the
mg/ml) or more, diluted protein solut:ions with fibrinogen cont.ents of from 2 to 7 ~ may be used accordiny to the invention, or there may be achieved adhesions of higher strengths when using protein solutions having fibrinogen contents of up to 12 %.
The invention is based on the principle that a favorable ra~io between the necessary reconstitution time of the protein lyophilisate and the strength of the adhesions will be obtained, if the hitherto usual mixing ratio of the protein solution and the thrombin solution of 1 is altered such that the protein component is dissolved in a relatively larger volume and the thrombin component is dissolved in a relatively smaller volume to compensate for the resulting lower protein concentration ~- of the protein component in the mixture of the two components.
If, however, adhesions of particularly high strengths are sought, an increase in the concentration of the adhesive proteins may be obtained according to the invention after having mixed the two components, without having to put up with~extended reconstitution times.
Mixing the two components in a su~ici~ntly exact ratio that deviates from 1 would be too difficult when using two separate syringes and has become possible only by the double syringe according to the invention.
The arrangement accordlng to the invention will now be explalned in more de-tail by way of two em~odiments and with reference -to the accompanying drawing, w~erein Figs.
1 an-l 2 are each a par~ially sectioned sidt3 vi63w oE the
- 4 -double syringe according to the invention.
In Fig. 1, a syringe body 1 is destined to contain the protein solution and a syringe body 2 is destined to contain the thrombin solution. Suitably, they are designed as disposable syringe bodies, made of synthe-tic material.
They are commonly inserted in U-shaped grooves 4, 5 of a holding means 3.
On the end of the holding means, finger grips 6 are provided, into which the flange ends 7 and 8 of the syringe bodies project such that the syringe bodies are fixed in the direction of their longitudinal axes. Pistons 21, 22 are guided in the syringe bodies, whose piston rods 9 and 10 project outwards. They comprise a common actuation means 11. A guiding rod 12 passes through a bore `;13 of the holding means.
: .
A connecting he~d 16 is attachable to the coni 14, 15 of the syringe bodies 1, 2 and incIudes conveying channels 17 and l8 ending in;ths front side 19 of the socket-like connecting head. A mixing needle 20 is attached to this -~20 socket.
-~As is apparent from~ the drawing, the syringe body 1 has a larger cross section than the syringe body 2; in the embodiment illustrated, the size ratio is 3 : 1, the -~volumes thus being 3 : l. The effectlve strokes of the two syringe bodies, i.e., the respective distances of the piston 21 and 22 entered in broken lines from the mouth sides 23, 2~, respectively, are identical.
With the modi~ied embodiment according to Fig. 2, the .
syringe bodies are designed as twin-chamber syringe bodies, with the lyophilized adhesive protein 26 being filled in the mouth-side chamber 25 of the syringe body 1 and thrombin 28 being filled in the mouth-side chamber 27 of the syringe body 2. In chambers 29 and 30 facing away from the mouth sides, the solvent is contained, viz., a solution containing aprotlnin in chamber 29 and a solution containing calcium chloride in chamber 30. Chambers 25 and 29 are separated by a floating piston 31, and chambers 27 and 30 are separated by a floating piston 32. By-passing ducts are denoted by 33 ~nd 34.
The pistons 21 and 22 are fastened to piston rods 9 and 10. Upon actuation of the same, the liquid is urged from chambers 29, 30 into chambers 25 and 27, respectively, via the by-passing ducts, thus preparing the solutions required for application. Even with this embodlment, the cross sectional ratio of syringe body 1 to syringe body 2 is 3 : l.
In the following Table, comparative assays are illus~rated, wherein, according to column "Standard", an adhesive protein solution was mixed with a thrombin :
solution at a volume ratio of l : l in the conventional manner by using the arrangement known from U.S. patent No.
4,359,049; according to columns 2 to 9, adhesive protein solutions having different fibrinogen contents were mixed with thrombin solutions in different mixing ratios by using the mode of operation and arrangements according to the invention, and the properties of the solidified , ~9~
adhesives were investigated.
The assays were carried out with a lyophilized tissue adhesive according to U.S. patent No. 4,414,976, wherein the sterile lyophilized preparations (each containing 370 mg dry substance, 200 mg thereof fibrinogen) contained in final containers at first were dissolved by applying the method described in Canadian patent No. 1,182,444 with so much solvent (aqua ad iniectabilia or aprotinin solution) that the fibrinogen concentrations indicated in column 2 of the Table were obtained. The dissolution time required in each case was determined and is indicated in column 4 of the Table.
The tissue adhesive solutions (first component) obtained as described were rapidly mixed with a thrombin-CaCl solution (second component) of the composition2 indicated in colums 5 and 6 at the volume ratio indicated in column 7 by using the application means according to the invention, were introduced into standardized separable casting molds and were incubated at 37 C for 30 minutes~
Subsequently, the solidified samples are removed from the casting molds, and the ultimate tensile strength was determined by means of an appropriate measuring device over a standardized cross section (0~0314 cm ). The results ob~ained (mean values of three measurements each, the individual values deviating from the mean value by no more than 15 ~) are summarized in the last column of the Table.
In col.umns 8 to 11, the final concentrations of fibri.nogen, aprotinin, thrombin and C:aC12 upon mixture of the two co~ponents are indicated.
From the results, it becomes apparent that the dissolution time required depends on the desired ~ fibrinogen concentra-tion in the first component (tissue - adhesive solution) prior to mixing the components, whereas the ultimate tensile strength depends on the final ~;~ concentration of flbrinogen upon mixture of the two components.
Thus, it has become possible, by using the application means according to the invention, to shorten the dissolution time required without deteriorating the ultimate tensile strength (Examples 1, 2, 3, 5, 6, 7) or, vice versa, to further increase the ultimate tensile strength without having to put up with extended dissolution times (Examples 8 and 9). Example 4 indicates that in some cases in which a slightly reduced ultimate tensile strength will do, extremely short dissolution times may be reached by using the application means according to the invention.
-; Example 5 reveals that the application means accordin~ to the invention is suited also for application of high thrombin concentrations; however, solidification -- of the tissue adhesive in such a case occurs so rapidly that the casting of standardized clots and hence the determination of the ultimate tensile strength are no longer possible~ Yet, the utilization of high thrombin concentrat.ions is o~ great importance in ~urgical i~24~9~
pxactice, in particular to stop bleedings.
A comparison of Examples 6 and 7 with Examples 1 to 3 finally proves that it is of no rel.evance either to the dissolution time required or to the ultimate tensile strength achieved, whether the dissolution of the lyophilized tissue adhesive is effected by means of aqua ad iniectabilia or by means of an aprotinin solution.
~' '~:
:
~:, _ g _ ~z~
~ - -- -------- --a u~ ~ u- ~ ~ C:~ ~D
~; ~ ~ Lr~ ~o u~ Ln a~ ~ I
Q~ ~ ~ ~ ~ _~ ~ O ~i _l ~r ~ ~ ~o 2 o o o o o o o o l ~ _ _ ___ _ _ _ ~
E ,_ O
3 ~ ~ H N . ~ : ~_ ~_ ~ r~l ~_ ~ t~
'~ r~ ~ .C;_ __ _ _ ~ . ~ ~ 8 ~ ~ o o l l 8 8 _ _ l r _ ~: ~ ~ O ~ ~ O ~ O O O ~ O
~ O -~
. .
., tn 00 ~ o ~o ~ h ~ : ~ ~ . r ~ ~ . ~~
~ ~ _ r l _ ~
~ ~ ~ ~o 8 ~o 8 o 8 gl ~ 8 ~ ~ , o __ .......... . _ . _ _ _ ~ ~ C. ~,~ I
~ ~ U~ ~ ~ I C3 O O ¦ O ~ C~ ¦ O c:~ O
- '-~ _ __ ~ I u~ ~__ ~ ~ e S I ~ D m 1 ~ ~ 1 ~
I I l I l I l I I ~ I
~ i ~ o ~ 8 8 ¦ 8 ¦ 8 ~ ~ N ~ - .
: o 1- c I -- I I -~---t------~, ~ ~ -~o ~ l l l l l O ~ D U~ O 8 8 .' ... ~ X~ o~ ~ Lr ~
In Fig. 1, a syringe body 1 is destined to contain the protein solution and a syringe body 2 is destined to contain the thrombin solution. Suitably, they are designed as disposable syringe bodies, made of synthe-tic material.
They are commonly inserted in U-shaped grooves 4, 5 of a holding means 3.
On the end of the holding means, finger grips 6 are provided, into which the flange ends 7 and 8 of the syringe bodies project such that the syringe bodies are fixed in the direction of their longitudinal axes. Pistons 21, 22 are guided in the syringe bodies, whose piston rods 9 and 10 project outwards. They comprise a common actuation means 11. A guiding rod 12 passes through a bore `;13 of the holding means.
: .
A connecting he~d 16 is attachable to the coni 14, 15 of the syringe bodies 1, 2 and incIudes conveying channels 17 and l8 ending in;ths front side 19 of the socket-like connecting head. A mixing needle 20 is attached to this -~20 socket.
-~As is apparent from~ the drawing, the syringe body 1 has a larger cross section than the syringe body 2; in the embodiment illustrated, the size ratio is 3 : 1, the -~volumes thus being 3 : l. The effectlve strokes of the two syringe bodies, i.e., the respective distances of the piston 21 and 22 entered in broken lines from the mouth sides 23, 2~, respectively, are identical.
With the modi~ied embodiment according to Fig. 2, the .
syringe bodies are designed as twin-chamber syringe bodies, with the lyophilized adhesive protein 26 being filled in the mouth-side chamber 25 of the syringe body 1 and thrombin 28 being filled in the mouth-side chamber 27 of the syringe body 2. In chambers 29 and 30 facing away from the mouth sides, the solvent is contained, viz., a solution containing aprotlnin in chamber 29 and a solution containing calcium chloride in chamber 30. Chambers 25 and 29 are separated by a floating piston 31, and chambers 27 and 30 are separated by a floating piston 32. By-passing ducts are denoted by 33 ~nd 34.
The pistons 21 and 22 are fastened to piston rods 9 and 10. Upon actuation of the same, the liquid is urged from chambers 29, 30 into chambers 25 and 27, respectively, via the by-passing ducts, thus preparing the solutions required for application. Even with this embodlment, the cross sectional ratio of syringe body 1 to syringe body 2 is 3 : l.
In the following Table, comparative assays are illus~rated, wherein, according to column "Standard", an adhesive protein solution was mixed with a thrombin :
solution at a volume ratio of l : l in the conventional manner by using the arrangement known from U.S. patent No.
4,359,049; according to columns 2 to 9, adhesive protein solutions having different fibrinogen contents were mixed with thrombin solutions in different mixing ratios by using the mode of operation and arrangements according to the invention, and the properties of the solidified , ~9~
adhesives were investigated.
The assays were carried out with a lyophilized tissue adhesive according to U.S. patent No. 4,414,976, wherein the sterile lyophilized preparations (each containing 370 mg dry substance, 200 mg thereof fibrinogen) contained in final containers at first were dissolved by applying the method described in Canadian patent No. 1,182,444 with so much solvent (aqua ad iniectabilia or aprotinin solution) that the fibrinogen concentrations indicated in column 2 of the Table were obtained. The dissolution time required in each case was determined and is indicated in column 4 of the Table.
The tissue adhesive solutions (first component) obtained as described were rapidly mixed with a thrombin-CaCl solution (second component) of the composition2 indicated in colums 5 and 6 at the volume ratio indicated in column 7 by using the application means according to the invention, were introduced into standardized separable casting molds and were incubated at 37 C for 30 minutes~
Subsequently, the solidified samples are removed from the casting molds, and the ultimate tensile strength was determined by means of an appropriate measuring device over a standardized cross section (0~0314 cm ). The results ob~ained (mean values of three measurements each, the individual values deviating from the mean value by no more than 15 ~) are summarized in the last column of the Table.
In col.umns 8 to 11, the final concentrations of fibri.nogen, aprotinin, thrombin and C:aC12 upon mixture of the two co~ponents are indicated.
From the results, it becomes apparent that the dissolution time required depends on the desired ~ fibrinogen concentra-tion in the first component (tissue - adhesive solution) prior to mixing the components, whereas the ultimate tensile strength depends on the final ~;~ concentration of flbrinogen upon mixture of the two components.
Thus, it has become possible, by using the application means according to the invention, to shorten the dissolution time required without deteriorating the ultimate tensile strength (Examples 1, 2, 3, 5, 6, 7) or, vice versa, to further increase the ultimate tensile strength without having to put up with extended dissolution times (Examples 8 and 9). Example 4 indicates that in some cases in which a slightly reduced ultimate tensile strength will do, extremely short dissolution times may be reached by using the application means according to the invention.
-; Example 5 reveals that the application means accordin~ to the invention is suited also for application of high thrombin concentrations; however, solidification -- of the tissue adhesive in such a case occurs so rapidly that the casting of standardized clots and hence the determination of the ultimate tensile strength are no longer possible~ Yet, the utilization of high thrombin concentrat.ions is o~ great importance in ~urgical i~24~9~
pxactice, in particular to stop bleedings.
A comparison of Examples 6 and 7 with Examples 1 to 3 finally proves that it is of no rel.evance either to the dissolution time required or to the ultimate tensile strength achieved, whether the dissolution of the lyophilized tissue adhesive is effected by means of aqua ad iniectabilia or by means of an aprotinin solution.
~' '~:
:
~:, _ g _ ~z~
~ - -- -------- --a u~ ~ u- ~ ~ C:~ ~D
~; ~ ~ Lr~ ~o u~ Ln a~ ~ I
Q~ ~ ~ ~ ~ _~ ~ O ~i _l ~r ~ ~ ~o 2 o o o o o o o o l ~ _ _ ___ _ _ _ ~
E ,_ O
3 ~ ~ H N . ~ : ~_ ~_ ~ r~l ~_ ~ t~
'~ r~ ~ .C;_ __ _ _ ~ . ~ ~ 8 ~ ~ o o l l 8 8 _ _ l r _ ~: ~ ~ O ~ ~ O ~ O O O ~ O
~ O -~
. .
., tn 00 ~ o ~o ~ h ~ : ~ ~ . r ~ ~ . ~~
~ ~ _ r l _ ~
~ ~ ~ ~o 8 ~o 8 o 8 gl ~ 8 ~ ~ , o __ .......... . _ . _ _ _ ~ ~ C. ~,~ I
~ ~ U~ ~ ~ I C3 O O ¦ O ~ C~ ¦ O c:~ O
- '-~ _ __ ~ I u~ ~__ ~ ~ e S I ~ D m 1 ~ ~ 1 ~
I I l I l I l I I ~ I
~ i ~ o ~ 8 8 ¦ 8 ¦ 8 ~ ~ N ~ - .
: o 1- c I -- I I -~---t------~, ~ ~ -~o ~ l l l l l O ~ D U~ O 8 8 .' ... ~ X~ o~ ~ Lr ~
Claims (10)
PROPERTY OR PRIVILEGE IS CLAIMED ARE DEFINED AS FOLLOWS:
1. An arrangement for applying a tissue adhesive that solidifies in situ by uniting with blood-clot-promoting coagulation factors comprising:
a plurality of syringe bodies ending in joining pieces;
a piston in each of said plurality of syringe bodies for commonly actuating said syringe bodies;
a connecting head attached to said joining pieces of said syringe bodies and provided with a separate conveying channel for each of the components to be applied;
each of said syringe bodies having equally effective strokes; and one of said syringe bodies having a cross-sectional area that is two to nine times larger than the cross-sectional area of the remaining syringe bodies, said one syringe body containing an adhesive protein solution having a fibrinogen content of from 3 to 12%.
a plurality of syringe bodies ending in joining pieces;
a piston in each of said plurality of syringe bodies for commonly actuating said syringe bodies;
a connecting head attached to said joining pieces of said syringe bodies and provided with a separate conveying channel for each of the components to be applied;
each of said syringe bodies having equally effective strokes; and one of said syringe bodies having a cross-sectional area that is two to nine times larger than the cross-sectional area of the remaining syringe bodies, said one syringe body containing an adhesive protein solution having a fibrinogen content of from 3 to 12%.
2. The arrangement of claim 1, wherein said adhesive protein solution is prepared from a lyophilisate.
3. The arrangement of clam 1, wherein a second of said plurality of syringe bodies contains a thrombin solution.
4. The arrangement of claim 1, further comprising, first floating piston means in said one syringe body for dividing said one syringe body into a first chamber and a second chamber; and first by-pass means in said one syringe body for allowing fluid from said second chamber to mix with fluid in said first chamber when said first floating piston means is adjacent said first by-pass means.
5. The arrangement of claim 4, further comprising:
second floating piston means in a second of said plurality of syringe bodies for dividing said second syringe body into a third chamber and a fourth chamber; and second by-pass means in said second syringe body for allowing fluid from said forth chamber to mix with fluid in said third chamber when said second floating piston means is adjacent said second by-pass means.
second floating piston means in a second of said plurality of syringe bodies for dividing said second syringe body into a third chamber and a fourth chamber; and second by-pass means in said second syringe body for allowing fluid from said forth chamber to mix with fluid in said third chamber when said second floating piston means is adjacent said second by-pass means.
6. The device of claim 4, wherein said first chamber contains the adhesive protein solution and said second chamber contains a solvent including aprotinin.
7. The device of claim 5, wherein the third chamber contains thrombin and the fourth chamber contains a solvent including calcium chloride.
8. A device for dispensing a plurality of interreactable fluid, comprising:
a plurality of syringe bodies a connecting head interconnecting the discharge ends of each of the syringe bodies;
first piston means in each of said syringe bodies for actuating said syringe bodies;
first floating piston means in one of said syringe bodies for dividing said one syringe body into a first chamber and a second chamber; and first by-pass means in said one syringe body for allowing fluid from said second chamber to mix with fluid in said first by-pass means in said one syringe body for allowing fluid from said second chamber to mix with fluid in said first chamber when said first floating piston means is adjacent said first by-pass means;
wherein said one syringe body has a cross-sectional area that is two to nine times larger than the cross-sectional area of the remaining syringe bodies.
a plurality of syringe bodies a connecting head interconnecting the discharge ends of each of the syringe bodies;
first piston means in each of said syringe bodies for actuating said syringe bodies;
first floating piston means in one of said syringe bodies for dividing said one syringe body into a first chamber and a second chamber; and first by-pass means in said one syringe body for allowing fluid from said second chamber to mix with fluid in said first by-pass means in said one syringe body for allowing fluid from said second chamber to mix with fluid in said first chamber when said first floating piston means is adjacent said first by-pass means;
wherein said one syringe body has a cross-sectional area that is two to nine times larger than the cross-sectional area of the remaining syringe bodies.
9. The device of claim 8, further comprising, second floating piston means in a second of said syringe bodies for dividing said second syringe body into third and fourth chambers;
second by-pass means in said second syringe body for allowing fluid from said fourth chamber to mix with fluid from said third chamber when said second floating piston means is adjacent said second by-pass means.
second by-pass means in said second syringe body for allowing fluid from said fourth chamber to mix with fluid from said third chamber when said second floating piston means is adjacent said second by-pass means.
10. The device of claim 8, further comprising means for commonly actuating said first piston means.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ATA1838/85 | 1985-06-20 | ||
AT0183885A AT382783B (en) | 1985-06-20 | 1985-06-20 | DEVICE FOR APPLICATING A TISSUE ADHESIVE |
Publications (1)
Publication Number | Publication Date |
---|---|
CA1249194A true CA1249194A (en) | 1989-01-24 |
Family
ID=3522110
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA000511285A Expired CA1249194A (en) | 1985-06-20 | 1986-06-11 | Arrangement for applying a tissue adhesive |
Country Status (8)
Country | Link |
---|---|
US (1) | US4735616A (en) |
EP (1) | EP0210160B2 (en) |
JP (1) | JPS61293443A (en) |
AT (2) | AT382783B (en) |
CA (1) | CA1249194A (en) |
DE (1) | DE3663109D1 (en) |
DK (1) | DK162739B (en) |
ES (1) | ES8707668A1 (en) |
Families Citing this family (257)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK475386D0 (en) * | 1986-10-03 | 1986-10-03 | Weis Fogh Ulla Sivertsen | METHOD AND APPARATUS FOR MANUFACTURING BIOLOGICAL SUBSTANCES |
US4978336A (en) * | 1987-09-29 | 1990-12-18 | Hemaedics, Inc. | Biological syringe system |
US4874368A (en) * | 1988-07-25 | 1989-10-17 | Micromedics, Inc. | Fibrin glue delivery system |
US4902281A (en) * | 1988-08-16 | 1990-02-20 | Corus Medical Corporation | Fibrinogen dispensing kit |
US5116315A (en) * | 1989-10-03 | 1992-05-26 | Hemaedics, Inc. | Biological syringe system |
US5104375A (en) * | 1989-10-16 | 1992-04-14 | Johnson & Johnson Medical, Inc. | Locking holder for a pair of syringes and method of use |
US4979942A (en) * | 1989-10-16 | 1990-12-25 | Johnson & Johnson Medical, Inc. | Two component syringe delivery system |
DE4025503A1 (en) * | 1989-11-21 | 1991-05-23 | Andreas Dr Lindner | Injecting reactive separate components into blood vessels - using needles terminating in common inclined plane for rapid mixing |
DE59006067D1 (en) * | 1989-11-21 | 1994-07-14 | Lindner Andreas Dr | INJECTION DEVICE. |
US5318524A (en) * | 1990-01-03 | 1994-06-07 | Cryolife, Inc. | Fibrin sealant delivery kit |
US5219328A (en) * | 1990-01-03 | 1993-06-15 | Cryolife, Inc. | Fibrin sealant delivery method |
US5185001A (en) * | 1990-01-18 | 1993-02-09 | The Research Foundation Of State University Of New York | Method of preparing autologous plasma fibrin and application apparatus therefor |
DK119490D0 (en) * | 1990-05-14 | 1990-05-14 | Unes As | Apparatus for the preparation of a concentrate of coagulation factors, such as the fibrinogen, from a blood portion |
US5644032A (en) * | 1990-08-06 | 1997-07-01 | Fibrin Corporation | Process for producing fibrinogen concentrates |
US5420250A (en) * | 1990-08-06 | 1995-05-30 | Fibrin Corporation | Phase transfer process for producing native plasma protein concentrates |
FR2668067B1 (en) * | 1990-10-23 | 1998-01-16 | Lg Medical Sa | SYRINGE FOR INJECTION OF A PRODUCT TOWARDS THE BODY OF A RECEIVER, PISTON FOR SYRINGE AND APPLICATION OF THIS SYRINGE TO THE INTRODUCTION OF A VASCULAR PROSTHESIS. |
US5221259A (en) * | 1990-12-27 | 1993-06-22 | Novoste Corporation | Wound treating device and method of using same |
US5419765A (en) * | 1990-12-27 | 1995-05-30 | Novoste Corporation | Wound treating device and method for treating wounds |
US5129882A (en) * | 1990-12-27 | 1992-07-14 | Novoste Corporation | Wound clotting device and method of using same |
DK68991D0 (en) * | 1991-04-17 | 1991-04-17 | Novo Nordisk As | HEADER |
DK167517B1 (en) * | 1991-11-11 | 1993-11-15 | Squibb & Sons Inc | CONTAINER FOR INCLUSION AND SEPARATION OF A FLUID, PRETTY BLOOD PLASMA, IN ITS INGREDIENTS |
US5368563A (en) * | 1991-12-18 | 1994-11-29 | Micromedics, Inc. | Sprayer assembly for physiologic glue |
US5290259A (en) * | 1993-02-18 | 1994-03-01 | Ultradent Products, Inc. | Double syringe delivery system |
US5383906A (en) * | 1993-05-12 | 1995-01-24 | Burchett; Mark T. | Nursing bottle with medication dispenser |
US5824012A (en) * | 1993-05-12 | 1998-10-20 | The Medicine Bottle Company, Inc. | Nursing bottle with medication dispenser |
AT400675B (en) * | 1993-10-18 | 1996-02-26 | Immuno Ag | SYRINGE SET FOR STORAGE AND APPLICATION OF A MULTI-COMPONENT MATERIAL, SYRINGE DEVICE AND ACTUATING DEVICE THEREFOR, AND METHOD FOR PRODUCING A FILLED, STERILE SYRINGE DEVICE |
AT400304B (en) * | 1994-02-28 | 1995-12-27 | Immuno Ag | DEVICE FOR APPLICATING A MULTI-COMPONENT TISSUE ADHESIVE |
US5474540A (en) * | 1994-03-25 | 1995-12-12 | Micromedics, Inc. | Fluid separation control attachment for physiologic glue applicator |
DE59509633D1 (en) * | 1994-06-28 | 2001-10-31 | Aventis Behring Gmbh | Device for spraying a mixture of two components |
NZ291205A (en) * | 1994-08-18 | 1997-12-19 | Nmt Group Plc | Syringe with self retracting offset needle |
US5464471A (en) * | 1994-11-10 | 1995-11-07 | Whalen Biomedical Inc. | Fibrin monomer based tissue adhesive |
US5605541A (en) | 1994-12-07 | 1997-02-25 | E. R. Squibb And Sons, Inc. | Fibrin sealant applicatoor |
US5585007A (en) | 1994-12-07 | 1996-12-17 | Plasmaseal Corporation | Plasma concentrate and tissue sealant methods and apparatuses for making concentrated plasma and/or tissue sealant |
US5733545A (en) * | 1995-03-03 | 1998-03-31 | Quantic Biomedical Partners | Platelet glue wound sealant |
AU708165B2 (en) * | 1995-06-06 | 1999-07-29 | Interpore International Inc. | Wound sealant preparation and application device and method |
WO1996039208A1 (en) | 1995-06-06 | 1996-12-12 | Quantic Biomedical Partners | Device and method for concentrating plasma |
US5814022A (en) * | 1996-02-06 | 1998-09-29 | Plasmaseal Llc | Method and apparatus for applying tissue sealant |
US5759169A (en) * | 1996-03-13 | 1998-06-02 | New York Blood Center Inc. | Fibrin sealant glue-gun |
AU715822B2 (en) * | 1996-03-15 | 2000-02-10 | Juridical Foundation The Chemo-Sero-Therapeutic Research Institute | Tissue adhesive suitable for spray application |
WO2000062828A1 (en) | 1996-04-30 | 2000-10-26 | Medtronic, Inc. | Autologous fibrin sealant and method for making the same |
JP2000509307A (en) * | 1996-04-30 | 2000-07-25 | メドトロニック,インコーポレイテッド | Method for producing autologous fibrin sealant |
WO1998012274A1 (en) * | 1996-09-23 | 1998-03-26 | Chandrashekar Pathak | Methods and devices for preparing protein concentrates |
US8003705B2 (en) * | 1996-09-23 | 2011-08-23 | Incept Llc | Biocompatible hydrogels made with small molecule precursors |
US20090324721A1 (en) * | 1996-09-23 | 2009-12-31 | Jack Kennedy | Hydrogels Suitable For Use In Polyp Removal |
US5968018A (en) * | 1996-10-30 | 1999-10-19 | Cohesion Corporation | Cell separation device and in-line orifice mixer system |
US5844087A (en) | 1996-11-05 | 1998-12-01 | Bayer Corporation | Method and device for delivering fibrin glue |
NZ335751A (en) | 1996-11-15 | 2001-01-26 | Bristol Myers Squibb Co | Devices and methods for applying a mixture of two or more liquid components to form a biomaterial |
US6613020B1 (en) | 1996-12-06 | 2003-09-02 | Bristol-Myers Squibb Company | Method of applying a mixture of two liquid components as well as a device for carrying out the method |
US6783514B2 (en) | 1997-01-31 | 2004-08-31 | United States Surgical Corporation | Fibrin sealant applicator |
AT405517B (en) * | 1997-02-27 | 1999-09-27 | Immuno Ag | FACTOR X-DELETION MUTANTS AND ANALOGS OF THEM |
AT405516B (en) * | 1997-02-27 | 1999-09-27 | Immuno Ag | FACTOR X-ANALOG WITH MODIFIED PROTEASE SPLIT |
US6063055A (en) * | 1997-04-14 | 2000-05-16 | Biosurgical Corporation | Turbulence mixing head for a tissue sealant applicator and spray head for same |
JP4129296B2 (en) | 1997-04-14 | 2008-08-06 | バクスター インターナショナル インコーポレーテッド | Fluid applicator that dispenses a measured volume using controlled suction |
US5971956A (en) * | 1997-04-15 | 1999-10-26 | Biosurgical Corporation | Medical suctioning apparatus and methods of use |
US6331172B1 (en) * | 1997-04-14 | 2001-12-18 | Baxter International Inc. | Applicator for dispensing measured quantities with use of controlled suction |
DE29711075U1 (en) * | 1997-06-25 | 1997-08-21 | Wenzler Medizintechnik Gmbh | Sclerosing agent injection device |
ES2227861T3 (en) | 1997-07-11 | 2005-04-01 | United States Surgical Corporation | FIBRINE TAIL APPLICATOR SYSTEM. |
AT406120B (en) | 1997-08-28 | 2000-02-25 | Immuno Ag | TISSUE ADHESIVE |
JP3401779B2 (en) * | 1997-09-09 | 2003-04-28 | ニプロ株式会社 | Biological tissue adhesive dispenser |
US6458095B1 (en) | 1997-10-22 | 2002-10-01 | 3M Innovative Properties Company | Dispenser for an adhesive tissue sealant having a housing with multiple cavities |
WO1999020328A2 (en) | 1997-10-22 | 1999-04-29 | Minnesota Mining And Manufacturing Company | Dispenser for an adhesive tissue sealant |
US6079868A (en) * | 1997-12-18 | 2000-06-27 | Advanced Bio Surfaces, Inc. | Static mixer |
CA2314900C (en) | 1997-12-19 | 2009-02-24 | United States Surgical Corporation | Fibrin mixture and dispenser assembly |
WO1999032173A1 (en) | 1997-12-19 | 1999-07-01 | United States Surgical Corporation | Two component dispenser system |
US6568434B2 (en) | 1998-02-04 | 2003-05-27 | Omrix Biopharmaceuticals S.A. | Receiver cup for a vessel housing a medicinal substance |
WO1999039642A1 (en) | 1998-02-04 | 1999-08-12 | Omrix Biopharmaceuticals S.A. | Device for storing a liquid medicinal substance |
US6884230B1 (en) | 1998-03-09 | 2005-04-26 | Baxter International Inc. | Dispensing head for a tissue sealant applicator and process of use |
US6047861A (en) * | 1998-04-15 | 2000-04-11 | Vir Engineering, Inc. | Two component fluid dispenser |
JP2002515309A (en) | 1998-05-21 | 2002-05-28 | バクスター・インターナショナル・インコーポレイテッド | Method of using sealant applicator and impact cleaning |
US6274090B1 (en) | 1998-08-05 | 2001-08-14 | Thermogenesis Corp. | Apparatus and method of preparation of stable, long term thrombin from plasma and thrombin formed thereby |
US6152943A (en) * | 1998-08-14 | 2000-11-28 | Incept Llc | Methods and apparatus for intraluminal deposition of hydrogels |
WO2000009074A2 (en) * | 1998-08-17 | 2000-02-24 | Baxter International Inc. | Variable output applicator and method for multi-component biologic fluid agents, and application method |
WO2000015117A1 (en) | 1998-09-17 | 2000-03-23 | Focal, Inc. | Self-cleaning fluid delivery device for medical applications |
US7314477B1 (en) | 1998-09-25 | 2008-01-01 | C.R. Bard Inc. | Removable embolus blood clot filter and filter delivery unit |
US6921380B1 (en) | 1998-10-01 | 2005-07-26 | Baxter International Inc. | Component mixing catheter |
US6471670B1 (en) | 1998-10-05 | 2002-10-29 | Karl Enrenfels | Fibrin sealant applicator system |
EP1128858A1 (en) * | 1998-11-13 | 2001-09-05 | Elan Pharma International Limited | Drug delivery systems and methods |
WO2000033764A1 (en) | 1998-12-04 | 2000-06-15 | Pathak Chandrashekhar P | Biocompatible crosslinked polymers |
US20080114092A1 (en) * | 1998-12-04 | 2008-05-15 | Incept Llc | Adhesion barriers applicable by minimally invasive surgery and methods of use thereof |
US6328229B1 (en) | 1998-12-18 | 2001-12-11 | Cohesion Technologies, Inc. | Low volume mixing spray head for mixing and dispensing of two reactive fluid components |
DE19910972C1 (en) * | 1999-03-09 | 2000-10-26 | Omrix Biopharm Sa | Device for applying a flowable medium, in particular a tissue adhesive |
US6383110B1 (en) | 1999-03-29 | 2002-05-07 | Synkinetics, Inc. | Nested modified-cam speed converter |
US6472162B1 (en) | 1999-06-04 | 2002-10-29 | Thermogenesis Corp. | Method for preparing thrombin for use in a biological glue |
AT410216B (en) | 1999-08-10 | 2003-03-25 | Baxter Ag | X-ANALOG FACTOR WITH IMPROVED ACTIVITY |
KR100349797B1 (en) | 1999-09-13 | 2002-08-22 | 주)녹십자 | Fibrin sealant delivery device |
US6314826B1 (en) | 1999-10-29 | 2001-11-13 | Synkinetics, Inc. | Nested speed converter bearing apparatus |
US6802822B1 (en) | 2000-03-31 | 2004-10-12 | 3M Innovative Properties Company | Dispenser for an adhesive tissue sealant having a flexible link |
WO2002005898A1 (en) * | 2000-07-17 | 2002-01-24 | Haemacure Corporation | Spray head for applying a multi-component mixture |
US6506365B1 (en) * | 2000-09-25 | 2003-01-14 | Baxter Aktiengesellschaft | Fibrin/fibrinogen binding conjugate |
WO2002030445A2 (en) * | 2000-10-13 | 2002-04-18 | Baxter International Inc. | Fibrinogen plus a non-plasmin-acting fibrinolysis inhibitor for the reduction or prevention of adhesion formation |
US20020165483A1 (en) * | 2000-11-10 | 2002-11-07 | Curtis Miller | Gas assisted spray applicator |
US7175336B2 (en) * | 2001-01-26 | 2007-02-13 | Depuy Acromed, Inc. | Graft delivery system |
US7008433B2 (en) * | 2001-02-15 | 2006-03-07 | Depuy Acromed, Inc. | Vertebroplasty injection device |
EP1372488B1 (en) | 2001-02-27 | 2008-02-13 | Tyco Healthcare Group Lp | External mixer assembly |
US20020172615A1 (en) * | 2001-03-08 | 2002-11-21 | Archie Woodworth | Apparatus for and method of manufacturing a prefilled sterile container |
US6723067B2 (en) | 2001-07-26 | 2004-04-20 | David H. Nielson | Apparatus for delivering aerosolized fibrin endoscopically to a wound |
US7923431B2 (en) | 2001-12-21 | 2011-04-12 | Ferrosan Medical Devices A/S | Haemostatic kit, a method of preparing a haemostatic agent and a method of promoting haemostatis |
US9204956B2 (en) | 2002-02-20 | 2015-12-08 | C. R. Bard, Inc. | IVC filter with translating hooks |
US20030229333A1 (en) * | 2002-02-22 | 2003-12-11 | Control Delivery Systems, Inc. | Methods for treating otic disorders |
US6863660B2 (en) | 2002-03-27 | 2005-03-08 | Hapio Biotech, Inc. | Fibrin applicator pistol |
US7374678B2 (en) * | 2002-05-24 | 2008-05-20 | Biomet Biologics, Inc. | Apparatus and method for separating and concentrating fluids containing multiple components |
US20030205538A1 (en) | 2002-05-03 | 2003-11-06 | Randel Dorian | Methods and apparatus for isolating platelets from blood |
US7992725B2 (en) | 2002-05-03 | 2011-08-09 | Biomet Biologics, Llc | Buoy suspension fractionation system |
US7832566B2 (en) | 2002-05-24 | 2010-11-16 | Biomet Biologics, Llc | Method and apparatus for separating and concentrating a component from a multi-component material including macroparticles |
WO2003099412A1 (en) * | 2002-05-24 | 2003-12-04 | Biomet Manufacturing Corp. | Apparatus and method for separating and concentrating fluids containing multiple components |
US7845499B2 (en) | 2002-05-24 | 2010-12-07 | Biomet Biologics, Llc | Apparatus and method for separating and concentrating fluids containing multiple components |
US20060278588A1 (en) | 2002-05-24 | 2006-12-14 | Woodell-May Jennifer E | Apparatus and method for separating and concentrating fluids containing multiple components |
US6936033B2 (en) | 2002-06-14 | 2005-08-30 | Medtronic, Inc. | Multiple ratio fluid dispenser |
US7217254B2 (en) * | 2002-09-20 | 2007-05-15 | Genzyme Corporation | Multi-pressure biocompatible agent delivery device and method |
PL377477A1 (en) * | 2002-12-11 | 2006-02-06 | Ferrosan A/S | Gelatine-based materials as swabs |
US7077339B2 (en) * | 2003-02-03 | 2006-07-18 | Biomet, Inc. | Spray applicator |
US20060264967A1 (en) | 2003-03-14 | 2006-11-23 | Ferreyro Roque H | Hydraulic device for the injection of bone cement in percutaneous vertebroplasty |
US8066713B2 (en) | 2003-03-31 | 2011-11-29 | Depuy Spine, Inc. | Remotely-activated vertebroplasty injection device |
WO2006011152A2 (en) | 2004-06-17 | 2006-02-02 | Disc-O-Tech Medical Technologies, Ltd. | Methods for treating bone and other tissue |
US8415407B2 (en) | 2004-03-21 | 2013-04-09 | Depuy Spine, Inc. | Methods, materials, and apparatus for treating bone and other tissue |
DE50309535D1 (en) | 2003-07-15 | 2008-05-15 | Straumann Holding Ag | System and method for mixing at least four components |
EP1656214B1 (en) * | 2003-08-21 | 2010-02-24 | Medmix Systems AG | Device and method for transferring, mixing and delivering components |
WO2005030034A2 (en) | 2003-09-26 | 2005-04-07 | Depuy Spine, Inc. | Device for delivering viscous material |
WO2005072700A2 (en) * | 2004-01-30 | 2005-08-11 | Ferrosan A/S | Haemostatic sprays and compositions |
AU2005262070B2 (en) * | 2004-07-09 | 2011-01-27 | Ferrosan Medical Devices A/S | Haemostatic composition comprising hyaluronic acid |
US7704267B2 (en) | 2004-08-04 | 2010-04-27 | C. R. Bard, Inc. | Non-entangling vena cava filter |
CA2579041A1 (en) * | 2004-09-07 | 2006-03-16 | Smith & Nephew, Inc. | Methods and devices for sterile field transfer |
JP4722455B2 (en) * | 2004-10-29 | 2011-07-13 | 株式会社吉野工業所 | Two-component mixing sprayer |
WO2006058153A1 (en) * | 2004-11-23 | 2006-06-01 | Smith & Nephew, Inc. | Composite mixer |
US20060178638A1 (en) * | 2004-12-03 | 2006-08-10 | Reynolds David L | Device and method for pharmaceutical mixing and delivery |
CN101180094B (en) * | 2004-12-23 | 2011-03-23 | 丰收技术股份有限公司 | Hydrating anhydrous graft materials |
US7866485B2 (en) | 2005-02-07 | 2011-01-11 | Hanuman, Llc | Apparatus and method for preparing platelet rich plasma and concentrates thereof |
WO2006086199A1 (en) * | 2005-02-07 | 2006-08-17 | Hanuman Llc | Platelet rich plasma concentrate apparatus and method |
US7708152B2 (en) | 2005-02-07 | 2010-05-04 | Hanuman Llc | Method and apparatus for preparing platelet rich plasma and concentrates thereof |
US7611494B2 (en) | 2005-02-08 | 2009-11-03 | Confluent Surgical, Inc. | Spray for fluent materials |
US7766900B2 (en) * | 2005-02-21 | 2010-08-03 | Biomet Manufacturing Corp. | Method and apparatus for application of a fluid |
US7635343B2 (en) * | 2005-04-21 | 2009-12-22 | Arteriocyte Medical Systems, Inc. | Fluid dispenser |
MX2007013932A (en) | 2005-05-12 | 2008-01-28 | Bard Inc C R | Removable embolus blood clot filter. |
US7468049B2 (en) * | 2005-06-14 | 2008-12-23 | Rieke Corporation | Dual syringe adapter |
US7575131B2 (en) * | 2005-07-13 | 2009-08-18 | Ethicon, Inc. | Multi-component delivery system |
US9381024B2 (en) | 2005-07-31 | 2016-07-05 | DePuy Synthes Products, Inc. | Marked tools |
US9918767B2 (en) | 2005-08-01 | 2018-03-20 | DePuy Synthes Products, Inc. | Temperature control system |
US8062327B2 (en) | 2005-08-09 | 2011-11-22 | C. R. Bard, Inc. | Embolus blood clot filter and delivery system |
DE102005041961B4 (en) * | 2005-09-03 | 2007-08-02 | Kettenbach Gmbh & Co. Kg | cartridge |
US9131999B2 (en) * | 2005-11-18 | 2015-09-15 | C.R. Bard Inc. | Vena cava filter with filament |
US8360629B2 (en) | 2005-11-22 | 2013-01-29 | Depuy Spine, Inc. | Mixing apparatus having central and planetary mixing elements |
US20100256669A1 (en) * | 2005-12-02 | 2010-10-07 | C.R. Bard, Inc. | Helical Vena Cava Filter |
CA2650473C (en) | 2006-04-24 | 2013-06-18 | Incept, Llc | Protein crosslinkers, crosslinking methods and applications thereof |
WO2007133366A2 (en) * | 2006-05-02 | 2007-11-22 | C. R. Bard, Inc. | Vena cava filter formed from a sheet |
EP1860665A1 (en) * | 2006-05-23 | 2007-11-28 | Comecer S.p.A. | Double needle element for dispensing radiofluids |
US8567609B2 (en) | 2006-05-25 | 2013-10-29 | Biomet Biologics, Llc | Apparatus and method for separating and concentrating fluids containing multiple components |
US8430813B2 (en) * | 2006-05-26 | 2013-04-30 | Depuy Spine, Inc. | Illuminated surgical access system including a surgical access device and integrated light emitter |
CA2655158A1 (en) * | 2006-06-05 | 2007-12-13 | C.R. Bard Inc. | Embolus blood clot filter utilizable with a single delivery system or a single retrieval system in one of a femoral or jugular access |
WO2008032322A2 (en) | 2006-09-14 | 2008-03-20 | Depuy Spine, Inc. | Bone cement and methods of use thereof |
US8603138B2 (en) * | 2006-10-04 | 2013-12-10 | Ethicon Endo-Surgery, Inc. | Use of an adhesive to treat intraluminal bleeding |
US7914511B2 (en) * | 2006-10-18 | 2011-03-29 | Ethicon Endo-Surgery, Inc. | Use of biosurgical adhesive as bulking agent |
AU2007311451A1 (en) | 2006-10-19 | 2008-04-24 | Depuy Spine, Inc. | Fluid delivery system |
US7441973B2 (en) * | 2006-10-20 | 2008-10-28 | Ethicon Endo-Surgery, Inc. | Adhesive applicator |
US7749235B2 (en) * | 2006-10-20 | 2010-07-06 | Ethicon Endo-Surgery, Inc. | Stomach invagination method and apparatus |
US7658305B2 (en) * | 2006-10-25 | 2010-02-09 | Ethicon Endo-Surgery, Inc. | Adhesive applier with articulating tip |
US8876844B2 (en) * | 2006-11-01 | 2014-11-04 | Ethicon Endo-Surgery, Inc. | Anastomosis reinforcement using biosurgical adhesive and device |
US7892250B2 (en) | 2006-11-01 | 2011-02-22 | Ethicon Endo-Surgery, Inc. | Use of biosurgical adhesive on inflatable device for gastric restriction |
US7833216B2 (en) * | 2006-11-08 | 2010-11-16 | Ethicon Endo-Surgery, Inc. | Fluid plunger adhesive dispenser |
US8057426B2 (en) * | 2007-01-03 | 2011-11-15 | Medtronic Vascular, Inc. | Devices and methods for injection of multiple-component therapies |
JP4988382B2 (en) * | 2007-02-28 | 2012-08-01 | ジーエルサイエンス株式会社 | Solid phase extraction device for sample solution |
US20080220047A1 (en) | 2007-03-05 | 2008-09-11 | Sawhney Amarpreet S | Low-swelling biocompatible hydrogels |
US20090227981A1 (en) | 2007-03-05 | 2009-09-10 | Bennett Steven L | Low-Swelling Biocompatible Hydrogels |
US20090227689A1 (en) | 2007-03-05 | 2009-09-10 | Bennett Steven L | Low-Swelling Biocompatible Hydrogels |
WO2008127639A1 (en) | 2007-04-12 | 2008-10-23 | Biomet Biologics, Llc | Buoy suspension fractionation system |
US8328024B2 (en) | 2007-04-12 | 2012-12-11 | Hanuman, Llc | Buoy suspension fractionation system |
US8067028B2 (en) | 2007-08-13 | 2011-11-29 | Confluent Surgical Inc. | Drug delivery device |
PL2259774T3 (en) | 2008-02-27 | 2013-04-30 | Biomet Biologics Llc | Methods and compositions for delivering interleukin-1 receptor antagonist |
WO2009111338A1 (en) | 2008-02-29 | 2009-09-11 | Biomet Manufacturing Corp. | A system and process for separating a material |
JP5569398B2 (en) | 2008-02-29 | 2014-08-13 | フェッローサン メディカル ディバイス エー/エス | Device for promoting hemostasis and / or wound healing |
US20110021982A1 (en) * | 2008-03-25 | 2011-01-27 | Medmix Systems Ag | Dispensing device with bypass |
US8182769B2 (en) | 2008-04-04 | 2012-05-22 | Biomet Biologics, Llc | Clean transportation system |
US8518272B2 (en) * | 2008-04-04 | 2013-08-27 | Biomet Biologics, Llc | Sterile blood separating system |
US8408480B2 (en) * | 2008-04-25 | 2013-04-02 | Confluent Surgical, Inc. | Self-cleaning spray tip |
US8033483B2 (en) | 2008-04-25 | 2011-10-11 | Confluent Surgical Inc. | Silicone spray tip |
AU2009244462B2 (en) | 2008-05-06 | 2013-04-11 | Cook Medical Technologies Llc | Apparatus and methods for delivering therapeutic agents |
US8012077B2 (en) * | 2008-05-23 | 2011-09-06 | Biomet Biologics, Llc | Blood separating device |
US8210453B2 (en) | 2008-09-12 | 2012-07-03 | Confluent Surgical, Inc. | Spray applicator |
EP2375960B1 (en) * | 2008-12-23 | 2018-10-31 | Cook Medical Technologies LLC | Apparatus for containing and delivering therapeutic agents |
US8187475B2 (en) | 2009-03-06 | 2012-05-29 | Biomet Biologics, Llc | Method and apparatus for producing autologous thrombin |
US8376989B2 (en) * | 2009-03-30 | 2013-02-19 | Covidien Lp | Compartmented syringe |
US8313954B2 (en) | 2009-04-03 | 2012-11-20 | Biomet Biologics, Llc | All-in-one means of separating blood components |
EP2424595A2 (en) * | 2009-04-30 | 2012-03-07 | Hyperbranch Medical Technology, Inc. | Self-contained medical applicators for surgical sealants, and methods of use thereof |
US8377507B2 (en) * | 2009-05-06 | 2013-02-19 | Synthes Usa, Llc | Method and apparatus for applying a sealant |
US9101744B2 (en) | 2009-05-29 | 2015-08-11 | Cook Medical Technologies Llc | Systems and methods for delivering therapeutic agents |
US8118777B2 (en) | 2009-05-29 | 2012-02-21 | Cook Medical Technologies Llc | Systems and methods for delivering therapeutic agents |
ES2332032B1 (en) | 2009-06-09 | 2010-06-07 | Grifols, S.A. | FIBRINA ADHESIVE APPLICATION DEVICE. |
US9011800B2 (en) | 2009-07-16 | 2015-04-21 | Biomet Biologics, Llc | Method and apparatus for separating biological materials |
AU2010278893B2 (en) | 2009-07-29 | 2014-02-27 | C.R. Bard, Inc. | Tubular filter |
US20110081398A1 (en) | 2009-10-01 | 2011-04-07 | Tyco Healthcare Group Lp | Multi-mechanism surgical compositions |
US20110081701A1 (en) * | 2009-10-02 | 2011-04-07 | Timothy Sargeant | Surgical compositions |
US8968785B2 (en) | 2009-10-02 | 2015-03-03 | Covidien Lp | Surgical compositions |
US9445795B2 (en) | 2009-10-16 | 2016-09-20 | Confluent Surgical, Inc. | Prevention of premature gelling of delivery devices for pH dependent forming materials |
US20110093057A1 (en) * | 2009-10-16 | 2011-04-21 | Confluent Surgical, Inc. | Mitigating Thrombus Formation On Medical Devices By Influencing pH Microenvironment Near The Surface |
US20110092922A1 (en) | 2009-10-19 | 2011-04-21 | Trompen Mick A | Transdermal dispensing apparatus and methods |
US8608642B2 (en) * | 2010-02-25 | 2013-12-17 | Ethicon Endo-Surgery, Inc. | Methods and devices for treating morbid obesity using hydrogel |
CA2730598C (en) | 2010-03-16 | 2018-03-13 | Confluent Surgical, Inc. | Modulating drug release rate by controlling the kinetics of the ph transition in hydrogels |
EP2550046B1 (en) | 2010-03-23 | 2019-04-24 | Hyperbranch Medical Technology, Inc. | Disposable syringe applicators for multi-component formulations |
CN102933243A (en) | 2010-04-05 | 2013-02-13 | 尼奥文股份有限公司 | Method and apparatus for wound sealant application |
US8591391B2 (en) | 2010-04-12 | 2013-11-26 | Biomet Biologics, Llc | Method and apparatus for separating a material |
US8697111B2 (en) | 2010-05-12 | 2014-04-15 | Covidien Lp | Osteochondral implant comprising osseous phase and chondral phase |
US8734824B2 (en) | 2010-05-27 | 2014-05-27 | Covidien LLP | Hydrogel implants with varying degrees of crosslinking |
US8591950B2 (en) | 2010-05-27 | 2013-11-26 | Covidien Lp | Hydrogel implants with varying degrees of crosslinking |
US8883185B2 (en) | 2010-05-27 | 2014-11-11 | Covidien Lp | Hydrogel implants with varying degrees of crosslinking |
US8734930B2 (en) | 2010-05-27 | 2014-05-27 | Covidien Lp | Hydrogel implants with varying degrees of crosslinking |
US8754564B2 (en) | 2010-05-27 | 2014-06-17 | Covidien Lp | Hydrogel implants with varying degrees of crosslinking |
US8968783B2 (en) | 2010-05-27 | 2015-03-03 | Covidien Lp | Hydrogel implants with varying degrees of crosslinking |
US8591929B2 (en) | 2010-05-27 | 2013-11-26 | Covidien Lp | Hydrogel implants with varying degrees of crosslinking |
US20120065666A1 (en) * | 2010-09-10 | 2012-03-15 | E. I. Du Pont De Nemours And Company | Seal-less device for dispensing microliter quantities of a material into a site |
SG189958A1 (en) * | 2010-10-22 | 2013-06-28 | Inex Innovations Exchange Private Ltd | Mixing device and uses thereof |
US8518440B2 (en) | 2010-12-21 | 2013-08-27 | Confluent Surgical, Inc. | Biodegradable osmotic pump implant for drug delivery |
US8440309B2 (en) | 2011-01-31 | 2013-05-14 | Confluent Surgical, Inc. | Crosslinked polymers with the crosslinker as therapeutic for sustained release |
EP2688940B1 (en) | 2011-03-24 | 2017-07-12 | Sofradim Production | Enzymatically degradable compositions |
WO2012150254A1 (en) | 2011-05-02 | 2012-11-08 | Baxter International Inc. | Fgf based fibrin binding peptides |
US9486190B2 (en) * | 2011-10-28 | 2016-11-08 | Medtronic Xomed, Inc. | Spray delivery system |
US10441959B2 (en) | 2011-10-28 | 2019-10-15 | Medtronic Xomed, Inc. | Multi-orifice spray head |
EP2822474B1 (en) | 2012-03-06 | 2018-05-02 | Ferrosan Medical Devices A/S | Pressurized container containing haemostatic paste |
US10010311B2 (en) * | 2012-04-11 | 2018-07-03 | St. Jude Medical Puerto Rico Llc | Sealant mixing containers for extra vascular bioadhesive delivery systems and methods |
AU2013275758B2 (en) | 2012-06-12 | 2015-03-12 | Ferrosan Medical Devices A/S | Dry haemostatic composition |
US8864892B2 (en) | 2012-06-21 | 2014-10-21 | Empire Technology Development Llc | Tailorable lignosulfonate carbonate adhesives |
DE102012012360A1 (en) * | 2012-06-22 | 2013-12-24 | Sca Schucker Gmbh & Co. Kg | Device for applying a pasty mass |
US10309430B2 (en) | 2012-08-10 | 2019-06-04 | Confluent Surgical, Inc. | Pneumatic actuation assembly |
US9642956B2 (en) | 2012-08-27 | 2017-05-09 | Biomet Biologics, Llc | Apparatus and method for separating and concentrating fluids containing multiple components |
EP2968873A4 (en) * | 2013-03-13 | 2016-10-26 | Applied Cardiovascular Solutions Llc | Methods, compositions, and devices for the occlusion of cavities and passageways |
US11931227B2 (en) | 2013-03-15 | 2024-03-19 | Cook Medical Technologies Llc | Bimodal treatment methods and compositions for gastrointestinal lesions with active bleeding |
US9950035B2 (en) | 2013-03-15 | 2018-04-24 | Biomet Biologics, Llc | Methods and non-immunogenic compositions for treating inflammatory disorders |
US9895418B2 (en) | 2013-03-15 | 2018-02-20 | Biomet Biologics, Llc | Treatment of peripheral vascular disease using protein solutions |
US10208095B2 (en) | 2013-03-15 | 2019-02-19 | Biomet Manufacturing, Llc | Methods for making cytokine compositions from tissues using non-centrifugal methods |
US20140271589A1 (en) | 2013-03-15 | 2014-09-18 | Biomet Biologics, Llc | Treatment of collagen defects using protein solutions |
US10143725B2 (en) | 2013-03-15 | 2018-12-04 | Biomet Biologics, Llc | Treatment of pain using protein solutions |
US9867931B2 (en) | 2013-10-02 | 2018-01-16 | Cook Medical Technologies Llc | Therapeutic agents for delivery using a catheter and pressure source |
AU2014283170B2 (en) | 2013-06-21 | 2017-11-02 | Ferrosan Medical Devices A/S | Vacuum expanded dry composition and syringe for retaining same |
EP3017773B1 (en) * | 2013-07-04 | 2023-07-19 | Terumo Kabushiki Kaisha | Syringe assembly |
EP3060131B1 (en) * | 2013-10-21 | 2019-12-11 | Accuro Technologies Inc. | Double barrel syringe and method to use same for placement confirmation and joint space injection |
JP6489485B2 (en) | 2013-12-11 | 2019-03-27 | フェロサン メディカル デバイシーズ エイ/エス | Dry composition containing an extrusion enhancing factor |
US10085729B2 (en) | 2014-03-06 | 2018-10-02 | Ethicon, Inc. | Methods and devices for forming biomedical coatings using variable mixing ratios of multi-part compositions |
EP3125774B1 (en) | 2014-04-04 | 2020-05-27 | HyperBranch Medical Technology, Inc. | Extended tip spray applicator for two-component surgical selant, and methods of use thereof |
BR112017007466B1 (en) | 2014-10-13 | 2021-03-02 | Ferrosan Medical Devices A/S | method for preparing a dry composition, method for reconstituting the dry composition, paste, dry composition, container, homeostatic kit, and, using a dry composition |
US10653837B2 (en) | 2014-12-24 | 2020-05-19 | Ferrosan Medical Devices A/S | Syringe for retaining and mixing first and second substances |
US11382731B2 (en) | 2015-02-27 | 2022-07-12 | Covidien Lp | Medical devices with sealing properties |
ES1138206Y (en) * | 2015-03-16 | 2015-06-29 | Moral Daniel Martin | DOUBLE BODY SYRINGE |
WO2016152527A1 (en) * | 2015-03-26 | 2016-09-29 | 株式会社ジーシー | Double syringe |
US9713810B2 (en) | 2015-03-30 | 2017-07-25 | Biomet Biologics, Llc | Cell washing plunger using centrifugal force |
DE102015206757A1 (en) * | 2015-04-15 | 2016-10-20 | Henkel IP & Holding GmbH | Mixing and dispensing device and method for the provision and application of an adhesive consisting of at least two components |
US9757721B2 (en) | 2015-05-11 | 2017-09-12 | Biomet Biologics, Llc | Cell washing plunger using centrifugal force |
US10918796B2 (en) | 2015-07-03 | 2021-02-16 | Ferrosan Medical Devices A/S | Syringe for mixing two components and for retaining a vacuum in a storage condition |
CH711347A1 (en) | 2015-07-22 | 2017-01-31 | Medmix Systems Ag | Dispensing device for two syringes. |
US9572555B1 (en) * | 2015-09-24 | 2017-02-21 | Ethicon, Inc. | Spray or drip tips having multiple outlet channels |
USD877890S1 (en) * | 2015-12-22 | 2020-03-10 | Guangzhou Bioseal Biotech Co., Ltd. | Reconstitution device |
USD877891S1 (en) * | 2015-12-22 | 2020-03-10 | Guangzhou Bioseal Biotech Co., Ltd. | Reconstitution and delivery device |
CA3019843C (en) | 2016-04-22 | 2023-08-01 | Accuro Technologies Inc. | Single slider double barrel syringe and method to use same for medical diagnostics, therapeutic use, and placement confirmation and joint space injection |
CN111065344B (en) * | 2017-09-08 | 2023-09-22 | 三养控股公司 | Sealant injector assembly |
AU2019266529A1 (en) | 2018-05-09 | 2020-12-03 | Ethicon Inc. | Method for preparing a haemostatic composition |
CN110464977A (en) * | 2019-08-27 | 2019-11-19 | 郑州大学第一附属医院 | A kind of device using Platelet-rich plasm filling tissue sinus |
WO2023069674A1 (en) * | 2021-10-22 | 2023-04-27 | Boston Scientific Medical Device Limited | Systems and methods for producing mixtures |
WO2023070070A1 (en) * | 2021-10-22 | 2023-04-27 | Boston Scientific Medical Device Limited | Systems for producing mixtures |
WO2023070066A1 (en) * | 2021-10-22 | 2023-04-27 | Boston Scientific Medical Device Limited | Systems and methods for producing mixtures |
CN115365028A (en) * | 2022-09-01 | 2022-11-22 | 上海利格泰医用设备有限公司 | PRP injection device |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AT9324B (en) * | 1901-10-30 | 1902-10-10 | Max Dr Med Schachmann | Medicinal double syringe. |
FR1051010A (en) * | 1952-02-21 | 1954-01-12 | New syringe for injection | |
US3223083A (en) * | 1960-09-09 | 1965-12-14 | President And Directors Of Geo | Method for adhesively securing together skin and other soft tissue and bone |
US4040420A (en) * | 1976-04-22 | 1977-08-09 | General Dynamics | Packaging and dispensing kit |
AT359652B (en) * | 1979-02-15 | 1980-11-25 | Immuno Ag | METHOD FOR PRODUCING A TISSUE ADHESIVE |
AT366916B (en) * | 1980-04-02 | 1982-05-25 | Immuno Ag | DEVICE FOR APPLICATING A TISSUE ADHESIVE BASED ON HUMAN OR ANIMAL PROTEINS |
AT371719B (en) * | 1980-08-25 | 1983-07-25 | Immuno Ag | METHOD AND DEVICE FOR ACCELERATING THE DISOLDERING OF SLAVE-LYOPHILIZED MEDICINAL PRODUCTS |
AT379311B (en) * | 1984-03-29 | 1985-12-27 | Immuno Ag | DEVICE FOR APPLICATING A TISSUE ADHESIVE |
-
1985
- 1985-06-20 AT AT0183885A patent/AT382783B/en not_active IP Right Cessation
-
1986
- 1986-06-11 CA CA000511285A patent/CA1249194A/en not_active Expired
- 1986-06-12 DE DE8686890174T patent/DE3663109D1/en not_active Expired
- 1986-06-12 AT AT86890174T patent/ATE42683T1/en not_active IP Right Cessation
- 1986-06-12 EP EP86890174A patent/EP0210160B2/en not_active Expired - Lifetime
- 1986-06-17 US US06/875,080 patent/US4735616A/en not_active Expired - Lifetime
- 1986-06-19 ES ES556300A patent/ES8707668A1/en not_active Expired
- 1986-06-19 DK DK288886A patent/DK162739B/en not_active Application Discontinuation
- 1986-06-19 JP JP61144679A patent/JPS61293443A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
ES556300A0 (en) | 1987-08-16 |
US4735616A (en) | 1988-04-05 |
EP0210160B2 (en) | 1992-07-15 |
EP0210160A1 (en) | 1987-01-28 |
AT382783B (en) | 1987-04-10 |
JPS61293443A (en) | 1986-12-24 |
DK288886D0 (en) | 1986-06-19 |
DK162739B (en) | 1991-12-09 |
ATA183885A (en) | 1986-09-15 |
ATE42683T1 (en) | 1989-05-15 |
DE3663109D1 (en) | 1989-06-08 |
ES8707668A1 (en) | 1987-08-16 |
DK288886A (en) | 1986-12-21 |
EP0210160B1 (en) | 1989-05-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA1249194A (en) | Arrangement for applying a tissue adhesive | |
US5980866A (en) | Tissue adhesive suitable for spray application | |
EP0085923B1 (en) | Fibrinogen preparation, process for its manufacture and use thereof | |
EP0253198B2 (en) | Single-component tissue adhesive and method for producing same | |
KR100345570B1 (en) | A stabilized mixture comprising fibrinogen | |
US5185001A (en) | Method of preparing autologous plasma fibrin and application apparatus therefor | |
US5318782A (en) | Method for preparing tissue repair promoting substances | |
EP0968008B1 (en) | A stabilized mixture comprising fibrinogen | |
DE3002933C2 (en) | Tissue adhesive | |
DE3225102C2 (en) | ||
US5702715A (en) | Reinforced biological sealants | |
WO2001097872B1 (en) | Bioadhesive compositions and methods of preparation and use | |
JPH0118055B2 (en) | ||
CA2351544A1 (en) | Stabilised protein preparations for a tissue adhesive | |
AT500670A1 (en) | DRUGS FOR LOCAL APPLICATION | |
CA2344280A1 (en) | Improved component mixing catheter | |
JPH08208504A (en) | Use of vwf-containing concentrate as medical treatment applied by combining with anti-thrombotic and thrombus-dissolving medical treatment | |
Kram et al. | Use of concentrated fibrinogen in experimental splenic trauma | |
EP1053756B1 (en) | Haemostatic composition | |
CA2253412C (en) | Microparticles and their use in wound therapy | |
RU2026090C1 (en) | Compound for adhesion of biological tissues | |
AU6561300A (en) | Agent for occluding blood vessels | |
BG62638B1 (en) | Self-adhesive fibrine glue | |
Kim et al. | Fibrin sealants in maxillofacial surgery: a introductory report | |
NAKAHARA | The Limited Time for the Safe Application of a Tourniquet |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MKEX | Expiry |